Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data
- PMID: 32154908
- PMCID: PMC7935468
- DOI: 10.1002/cncr.32785
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURES
Please see the conflicts of interest declarations in the manuscript.
Comment on
-
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4. Cancer. 2019. PMID: 31483485 Free PMC article.
-
Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.Cancer. 2020 Jun 15;126(12):2934-2935. doi: 10.1002/cncr.32786. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154909 No abstract available.
Similar articles
-
Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.Cancer. 2020 Jun 15;126(12):2934-2935. doi: 10.1002/cncr.32786. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154909 No abstract available.
-
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4. Cancer. 2019. PMID: 31483485 Free PMC article.
-
Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer.Clin Genitourin Cancer. 2019 Jun;17(3):238-239. doi: 10.1016/j.clgc.2019.03.016. Epub 2019 Apr 1. Clin Genitourin Cancer. 2019. PMID: 31015016 No abstract available.
-
Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.Expert Rev Vaccines. 2015;14(12):1529-41. doi: 10.1586/14760584.2015.1099437. Epub 2015 Oct 21. Expert Rev Vaccines. 2015. PMID: 26488270 Review.
-
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.PLoS One. 2018 Dec 5;13(12):e0208063. doi: 10.1371/journal.pone.0208063. eCollection 2018. PLoS One. 2018. PMID: 30517165 Free PMC article.
References
-
- Dores GM, Niu MT, Izurieta HS. Letter to the Editor: Potential understimation of cerebrovascular events in the Provenge Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer. TBD. - PubMed
-
- Malarkey MA, Witten CM. April 29, 2010 Approval Letter - Provenge to Dendreon Corporation. In: Smith EC, editor. Bethesda, MD, 2010.
-
- Higano CS, Armstrong AJ, Sartor AO, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019;125: 4172–4180. - PubMed
-
- Dendreon Data On File. PROCEED Registry Records. Seattle, WA: Dendreon Pharmaceuticals LLC.
-
- Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017Adverse Events Associated With Use of Sipuleucel-T Reported to FDAAdverse Events Associated With Use of Sipuleucel-T Reported to FDA. JAMA Network Open. 2019;2: e199249–e199249. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources